De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Publication | Closed Access

DOI

Citations

References

2022

Year

Ulrike Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, Michael Braun, Doris Augustin, Jochem Potenberg, Katja Krauss,

The Lancet Oncology

Breast OncologyMedicineTrastuzumab TherapyClinical TrialsWeekly PaclitaxelBreast CancerPharmacotherapyDe-escalated Neoadjuvant PertuzumabCancer TreatmentOncologyRadiation OncologyHealth Sciences